Ernexa Therapeutics Inc.
ERNANASDAQHealthcare● Active
$7.62
+$0.23(+3.11%)
Market Cap$2393625
P/E Ratio—
52W High$71.5
52W Low$3.18
Ernexa Therapeutics Inc. (ERNA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ERNA · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | ($0.00B) | $0.00B | $0.00B |
| Gross Margin %(computed) | — | 83.51% | -247.06% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.01B | $0.01B | $0.01B |
| G&A Expenses | $0.01B | $0.01B | $0.01B | $0.02B | $0.01B |
| Total Operating Expenses | $0.01B | $0.02B | $0.02B | $0.03B | $0.11B |
| Operating Income | ($0.01B) | ($0.02B) | ($0.02B) | ($0.03B) | ($0.11B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.01B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.01B) | ($0.04B) | ($0.02B) | ($0.02B) | ($0.12B) |
| Income Tax Expense | ($0.00B) | $0.00B | ($0.00B) | $0.00B | $0.00B |
| Net Income | ($0.01B) | ($0.04B) | ($0.02B) | ($0.02B) | ($0.12B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-56.00 | $-39.25 | $-102.00 | $-201.50 | $-1415.25 |
| Wtd Avg Shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| EBITDA | ($0.01B) | ($0.04B) | ($0.02B) | ($0.02B) | ($0.12B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Ernexa Therapeutics Inc. data
About Ernexa Therapeutics Inc. (ERNA) Income Statement
Ernexa Therapeutics Inc. (ERNA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ERNA reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.01B) — a net profit margin of —.
Frequently asked questions
ERNA · 4 questionsErnexa Therapeutics Inc. (ERNA) reported revenue of $0.00B for 2025, down 100.0% year-over-year.
ERNA revenueERNA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09